

TANDEM DIABETES CARE INC
Form 8-K
July 30, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2015

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36189	20-4327508
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

11045 Roselle Street, San Diego, CA 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (858) 366-6900

N/A

(Former name or former address, if changed since last report)

Edgar Filing: TANDEM DIABETES CARE INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2015, we issued a press release announcing our financial results for the quarter ended June 30, 2015. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information provided under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On July 30, 2015, we issued a press release announcing that we have entered into Development Agreements with Dexcom to allow the integration of future generation Tandem insulin pumps with the Dexcom G5 and G6 continuous glucose monitoring systems. The press release announcing the Development Agreements is attached hereto as Exhibit 99.2 and is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number	Description
--------	-------------

- | | |
|------|---|
| 99.1 | Press release of Tandem Diabetes Care, Inc. dated July 30, 2015, announcing second quarter 2015 financial results. |
| 99.2 | Press release of Tandem Diabetes Care, Inc. dated July 30, 2015, announcing entering into Development Agreements with Dexcom. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

Date: July 30, 2015 /s/ David B. Berger
David B. Berger
General Counsel and Secretary

INDEX TO EXHIBITS

Number Description

- | | |
|------|---|
| 99.1 | Press release of Tandem Diabetes Care, Inc. dated July 30, 2015, announcing second quarter 2015 financial results. |
| 99.2 | Press release of Tandem Diabetes Care, Inc. dated July 30, 2015, announcing entering into Development Agreements with Dexcom. |